How does circVec technology compare to conventional mRNA expression?
Drug Discovery World
JULY 3, 2024
Circio has announced updated in vivo data that demonstrates a substantial durability advantage of Circio’s circVec technology over conventional mRNA expression. In addition, Circio has undertaken sequence optimisation resulting in a new circVec 2.2 design. “The circVec 2.1 design is performing very well in vivo , and Circio has now validated expression for up to five months.
Let's personalize your content